|
|
|
BERKELEY, Calif., Nov. 19, 2009 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced that it received a letter from the staff of The NASDAQ Stock Market LLC...
Nov 18 (Reuters) - : * Canaccord adams starts Cytokinetics Inc with buy rating; price target of $7 * Canaccord adams starts Momenta Pharmaceuticals with buy rating; price target of $17 * Canaccord adams starts XOMA Ltd with buy...
BERKELEY, Calif., Nov. 17, 2009 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced that James R. Neal has joined the company as Vice President,...
ThromboGenics NV (Euronext Brussels: THR) and BioInvent International AB (OMXS: BINV) announced positive results from a Phase I trial of their novel anti-cancer monoclonal antibody TB-403 in patients with advanced solid...
BioInvent International AB (OMXS: BINV) has announced that it has entered into a licence and discovery agreement with DAIICHI SANKYO COMPANY, LIMITED (TSE: 4568) for the development of therapeutic antibodies against multiple...
67 WALL STREET, New York - The Wall Street Transcript has recently published its Biotechnology Report offering a timely review of the sector to serious investors and industry executives. Gene Delivery Technology Companies...
67 WALL STREET, New York - November 13, 2009 - The Wall Street Transcript has just published its Biotechnology Report offering a timely review of the sector to serious investors and industry executives. This 70 page feature...
NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by TheFortuneFinancial.com. NEW DELHI, INDIA--(Marketwire - November 13, 2009) - TheFortuneFinancial.com provides the highest level of independent research...
BioInvent International ABPosted on:13 Nov 09 BioInvent International AB (OMXS: BINV) has announced that it has entered into a licence and discovery agreement with DAIICHI SANKYO COMPANY, LIMITED (TSE: 4568) for the development...
BERKELEY, Calif., Nov. 12, 2009 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced its anti-inflammatory antibody to interleukin-1 beta (IL-1 beta), XOMA...
